Abstract:The current research is aimed at formulation and in-vivo evaluation of dasatinib solid lipid nanoparticles (SLN) for enhanced solubility and bioavailability. A 33 Box-Behnken design (BBD) was used to optimize the formulations in which amount of glycerol monosterate(X1) the amount of poloxamer 407 (X2) and amount of tyloxopol (X3) were chosen as independent variables while particle size, entrapment efficiency and drug release after 12 hours were chosen as dependent variables. About 17 SLN formulations of dasatinib were prepared using glyceryl monostearate, poloxamer 407, Tyloxopol and Tween 80 and optimised using desirability function. All the SLNs were evaluated for fourier transform infrared spectroscopy (FTIR), particle size, zeta potential, entrapment efficiency and drug release behavior were investigated. The in-vivo pharmacokinetic evaluation of opimised SLN was carried out in rats. Based on BBD and desirability function the formulation comprising of X1:10, X2:06 and X3:02 was chosen optimal. The model was proven to be validated since a fine agreement existed between the predicted and observed results. It can be seen that the experimental values were in very close agreement with the predicted values, indicating the success of the BBD combined with a desirability function for the evaluation and optimization of SLNs formulations. The formulation DF10 displayed a mean particle size of 112 nm with PI of 0.40 and zeta potential of −25.6 mV.The in-vitro release studies showed that more than 98.78% of drug was released from optimized SLN after 12 hours, which is higher when compared with marketed formulation. The release kinetics of the optimized formulation followed zero order drug release and best fitted the Korsemeyer-peppas model. At any time, point, the drug plasma concentrations in animals administrated with optimized SLN was higher than that of pure drug. Cmax of the dasatinib optimised SLN 158.26 ± 0.54 ng/mL was significant (p < 0.05) as compared to the pure drug suspension formulation 32.08 ± 0.21 ng/mL. Tmax of both optimised SLN formulation and pure drug was 1.0 ± 0.47 and 1.0 ± 0.04 hour, respectively AUC0-∞ infinity for dasatinib optimised SLN formulation was higher (702.23 ± 1.26 ng.h/mL) than the pure drug suspension 191.67 ± 1.27 ng.h/mL. Statistically, AUC0-t of the optimised SLN formulation was significantly higher (p < 0.05) as compared to pure drug suspension formulation. These results indicated that the dasatinib-loaded SLN formulation could potentially be exploited for the treatment of chronic myelogenous leukemia with controlled release manner.

Optimization of Solid Lipid Nanoparticles of Ezetimibe in Combination with Simvastatin Using Quality by Design (QbD)

Single-component Solid Lipid Nanocarriers Prepared with Ultra-Long Chain Amphiphilic Lipids.

A Quality by Design Approach for Optimizing Solid Lipid Nanoparticles of Bedaquiline for Improved Product Performance

QbD-based systematic development of novel optimized solid self-nanoemulsifying drug delivery systems (SNEDDS) of lovastatin with enhanced biopharmaceutical performance

Sustained release biodegradable solid lipid microparticles: Formulation, evaluation and statistical optimization by response surface methodology

Quality by design (QbD) in the formulation and optimization of liquid crystalline nanoparticles (LCNPs): A risk based industrial approach

Ezetimibe-Loaded Nanostructured Lipid Carrier for Oral Delivery: Response Surface Methodology; In Vitro Characterization and Assessing the Antihyperlipidemic Effect in Rats

Quality-by-design based fabrication of febuxostat-loaded nanoemulsion: Statistical optimization, characterizations, permeability, and bioavailability studies

Glyceryl Monooleate/Poloxamer 407 Cubic Nanoparticles As Oral Drug Delivery Systems: I. in Vitro Evaluation and Enhanced Oral Bioavailability of the Poorly Water-Soluble Drug Simvastatin

Development of antihyperlipidemic drug loaded β-CD-based microparticulate carrier systems: tuning and optimization

Formulation Optimization and Characterization of Solid Lipid Nanoparticles of Apixaban

Systematic Approach for the Formulation and Optimization of Solid Lipid Nanoparticles of Efavirenz by High Pressure Homogenization Using Design of Experiments for Brain Targeting and Enhanced Bioavailability

Development, optimization, and in vitro evaluation of atorvastatin calcium and vinpocetine codelivery by solid lipid nanoparticles for cancer therapy

Formulation Design, Characterization and In-Vivo Assessment of Cefixime Loaded Binary Solid Lipid Nanoparticles to Enhance Oral Bioavailability.

Formulation of Solid Lipid Nanoparticles Loaded with Rosiglitazone and Probiotic: Optimization and In-vitro Characterization

Lipospheres for Simultaneous Controlled Release and Improved Pharmacokinetic Profiles of Saxagliptin-Enalapril: Formulation, Optimization, and Comparative In Vitro-In Vivo Evaluation

Therapeutic advancement of simvastatin-loaded solid lipid nanoparticles (SV-SLNs) in treatment of hyperlipidemia and attenuating hepatotoxicity, myopathy and apoptosis: Comprehensive study

Formulation and In-vivo Evaluation of Dasatinib-loaded Solid Lipid Nanoparticles

Quality by Design-Driven Zeta Potential Optimisation Study of Liposomes with Charge Imparting Membrane Additives

A quality by design (QbD) case study on liposomes containing hydrophilic API: II. Screening of critical variables, and establishment of design space at laboratory scale

Optimization of atorvastatin and quercetin-loaded solid lipid nanoparticles using Box-Behnken design